HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

J. Biol. Chem., Vol. 279, Issue 27, 27965-27970, July 2, 2004

This Article Abstract Full Text (PDF) All Versions of this Article: 279/27/27965    most recent M401295200v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Vindis, C. Articles by Huynh-Do, U. Search for Related Content PubMed PubMed Citation Articles by Vindis, C. Articles by Huynh-Do, U. Social Bookmarking                      What's this?

EphB1-mediated Cell Migration Requires the Phosphorylation of Paxillin at Tyr-31/Tyr-118^*

Cécile Vindis, Thalia Teli, Douglas P. Cerretti, Christopher E. Turner¶, and Uyen Huynh-Do||

From the Division of Nephrology and Department of Clinical Research, University of Bern, CH-3010 Bern, Switzerland, Amgen Corporation, Seattle, Washington 98101, and ^¶Department of Cell and Developmental Biology, State University of New York Upstate Medical University, Syracuse, New York 13210

Received for publication, February 5, 2004 , and in revised form, April 13, 2004.

	ABSTRACT

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES

 
Interactions between Eph receptors and their membrane-bound ligands (ephrins) are of critical importance for key developmental processes such as boundary formation or vascular development. Their downstream signaling pathways are intricate and heterogeneous at several levels, the combined effect being a highly complex and flexible system. Here we demonstrate that activated EphB1 induces tyrosine phosphorylation of the focal adhesion protein paxillin at Tyr-31 and Tyr-118 and is recruited to paxillin-focal adhesion kinase (FAK) complexes. Pretreatment with the specific Src inhibitor PP2, or expression of dominant-negative, kinase-dead c-Src abrogates EphB1-induced tyrosine phosphorylation of paxillin. Cells transfected with the paxillin mutant Y31F/Y118F displayed a reduced migration in response to ephrin B2 stimulation. Furthermore, expression of an LD4 deletion mutant (paxillin LD4) significantly reduces EphB1-paxillin association, paxillin tyrosine phosphorylation, as well as EphB1-dependent cell migration. Finally, mutation of the Nck-binding site of EphB1 (Y594F) interrupts the interaction between Nck, paxillin, and EphB1. These data suggest a model in which ligand-activated EphB1 forms a signaling complex with Nck, paxillin, and focal adhesion kinase and induces tyrosine phosphorylation of paxillin in a c-Src-dependent manner to promote cell migration.

	INTRODUCTION

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES

 
The Eph family of receptor tyrosine kinases and their membrane-bound ligands, the ephrins, are key regulators of several developmental processes, including cell migration, boundary formation, axonal guidance, synaptogenesis, and angiogenesis. Both receptor- and ligand-initiated signals mediate repulsion, adhesion, and de-adhesion mechanisms involved in the motility of adherent cells. After activation by their cognate ligands, Eph receptors are phosphorylated at specific tyrosine residues in the cytoplasmic domain, thus displaying new docking sites for known signaling molecules. Indeed, a variety of Src homology domain (SH2/SH3)-containing proteins have been identified as Eph receptor-binding partners, including the adaptor proteins Nck, Grb10, Grb7, SHEP-1, SLAP, the low molecular weight phosphotyrosine phosphatase LMW-PTP, the tyrosine kinases Crk, Fyn, and Src, the phosphatidylinositol-3 kinase, and the Ras GTPase-activating protein (reviewed in Ref. 1). Furthermore, PDZ-binding motifs located at the C terminus of the Eph receptors bind PDZ domain containing proteins such as AF6, Ryk (an RTK-interacting protein), Pick1, syntenin, and the two glutamate receptor-interacting proteins, Grip1 and Grip2 (2).

Importantly, many of the proteins identified in the Eph signaling pathways have been implicated in the regulation of cell morphology, adhesion, and motility. Activation of Eph receptors and ephrins has been shown to affect cell attachment by means of integrin and focal adhesion protein-dependent mechanisms, but contradictory results have been described for the interplay between these systems. In previous works, we showed that EphB1 receptor regulates integrin-dependent cell adhesion through activation of c-Jun kinase by means of Nck-interacting Ste20 kinase (NIK)¹ in endothelial and neuronal cells (3, 4). Subsequently, Miao et al. (5) showed that stimulation of EphA2 receptor with soluble ephrin A1 ligand results in an inhibition of integrin function and cell adhesion. However Carter et al. (6) demonstrated that ephrin A1 induces cell adhesion and actin cytoskeletal changes in fibroblasts in a focal adhesion kinase (FAK)-dependent and p130^cas-dependent manner through activation of EphA2 receptor. Furthermore, activation of ephrinA5 in transfected NIH-3T3 cells enhanced cell adhesion and formation of focal adhesions (7). More recently, we demonstrated that ligand-activated EphB1 forms a signaling complex with c-Src kinase and p52^Shc adaptor protein to promote extracellular signal-regulated kinases (ERK)1/2 activation and chemotaxis (8).

Because cell migration is a highly coordinated process involving continuous re-organization of the cell cytoskeleton, we hypothesized that molecules involved in focal adhesion signaling represent potential targets for activated EphB1. In this study, we provide evidence that ligand-stimulated EphB1 associates with the focal adhesion proteins paxillin and FAK and induces their tyrosine phosphorylation. Furthermore, c-Src-mediated paxillin phosphorylation at Tyr-31 and Tyr-118 is required for EphB1-induced cell migration. In addition, we show that the paxillin LD4 motif and the Nck-binding site of EphB1 (Tyr-594) are necessary for EphB1-paxillin interaction. Expression of an LD4 deletion mutant (paxillin LD4) decreases tyrosine phosphorylation of paxillin at Tyr-31 and Tyr-118, as well as cell migration in response to EphB1 stimulation. Based on these data, we propose a model in which the concerted actions of EphB1, Nck, and paxillin regulate cell migration in an Src-dependent manner.

	EXPERIMENTAL PROCEDURES

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES

 
Reagents—Cell culture reagents and fibronectin were obtained from Invitrogen AG (Basel, Switzerland); ephrin B2/Fc was obtained from Amgen (Seattle, WA). Control human IgG1 and suramin were purchased from Sigma-Aldrich Chemie (Steinheim, Germany), and PP2 and PP3 were obtained from Calbiochem (La Jolla, CA). The following antibodies were used: rabbit anti-paxillin (Santa Cruz Biotechnology, Santa Cruz, CA), phosphospecific anti-pTyr-31-paxillin and anti-pTyr-118-paxillin (BIOSOURCE, Camarillo, CA), monoclonal anti-Nck and anti-FAK (Transduction Laboratories, Lexington, KY), goat anti-EphB1 (R & D Systems, Minneapolis, MN), monoclonal anti-hemagglutinin (HA) (12CA5; Roche Applied Science), polyclonal anti-active mitogen-activated protein kinase (MAPK; Promega, Madison, WI), and anti-ERK1/2 and anti-phosphotyrosine 4G10-HRP (Upstate Biotechnology, Lake Placid, NY). ECL chemoluminescence kit and ECL phosphorylation module anti-phosphotyrosine horseradish peroxidase (HRP)-conjugate were obtained from Amersham (Buckinghamshire, UK).

Cell Culture and Transfection—P19 cells were cultured in -minimum Eagle's medium (MEM) with 10% fetal calf serum; primary human renal microvascular endothelial cells (HRMEC) were isolated and cultured as described (11). Chinese hamster ovary (CHO)-EphB1 cells expressing HA-tagged EphB1 receptor have been described previously (8) and were cultured in Dulbecco's modified Eagle's medium-F12 with 10% fetal calf serum containing Zeocin (Invitrogen AG). For transient transfections, CHO cells were seeded onto 100-mm plates and incubated in culture medium for 24 h before transfection. Cells were transfected using LipofectAMINE Plus with the plasmids encoding vector, wild-type paxillin, paxillin LD4 or LD2 deletion mutants (paxillin LD4 or paxillin LD2) (9), or paxillin Y31F/Y118F mutant (10). The EphB1 plasmids and dominant-negative Src have been described previously (8). Cotransfection of the plasmid enhanced green fluorescent protein (pEGFP) was used at 1 µg/100-mm plate as a marker of transfection efficiency (about 70%). Cells were used for biochemical or functional assays 48 h later.

Western Blotting and Immunoprecipitation—Cells were serum-starved for 24 h (P19, HRMEC) or 48 h (CHO-EphB1) in Opti-MEM and then stimulated for the indicated times at 37 °C with 0.5–1 µg ml^–1 of ephrin B2/Fc as described previously (8). For assessment of ERK1/2 activation and paxillin phosphorylation, cells were lysed in radioimmune precipitation assay buffer, and 40 µg of proteins were loaded on an SDS-10% PAGE. After transfer to Immobilon/polyvinylidene difluoride membranes (Millipore, Bedford, MA), the membranes were blocked 1% in bovine serum albumin. Phosphorylated ERK1/2 was detected with phosphospecific anti-phospho MAPK, whereas tyrosine-phosphorylated paxillin was detected with antibodies specifically recognizing phosphorylated Tyr-31 and Tyr-118 of paxillin. Membranes were stripped and reprobed with anti-ERK1/2 and anti-paxillin antibodies, respectively. For co-immunoprecipitations, cells were lysed in buffer containing 1% Triton X-100, 20 mM Hepes, pH 7.5, 150 mM NaCl, 10 mM NaF, 5 mM EDTA, 60 mM N-octyl-glucoside, 0.1% SDS supplemented with 1 mM orthovanadate and protease inhibitors. Immunoprecipitations were performed with the indicated antibodies for 2 h at 4 °C as described previously (11).

Cell Migration—For migration assays, a modified Boyden chamber system was used as described previously (8). Briefly, serum-starved cells were resuspended in Opti-MEM and seeded on fibronectin-coated Transwell inserts with 8-µM pore size membranes (Costar, Corning, NY). 1–2 µg ml^–1 clustered ephrin B2/Fc was added to the lower chamber, and then cells were allowed to migrate for 6 h at 37 °C. Non-migrating cells were removed with a cotton swab, and migrated cells were fixed with glutaraldehyde, stained with 0.5% crystal violet, and then eluted with acetic acid. Cell migration was quantified by a spectrophotometric reading at A₅₇₀.

	RESULTS

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES

 
Ligand-activated EphB1 Induces Phosphorylation of Paxillin at Tyr-31 and Tyr-118 —Cell movement requires a cytoskeletal re-organization involving phosphorylation of cytoskeleton-associated tyrosine kinases and the formation of focal adhesions. Because of the key role of EphB1 receptor in cell-cell and cell-matrix interactions, we anticipated that EphB1 activation would not only induce integrin "inside-out" activation (3), but that it would also affect focal adhesion complexes. In the present study, using two well established cellular systems expressing EphB1 (8, 12), we found that paxillin, a focal adhesion-associated docking protein, was tyrosine phosphorylated in response to EphB1 stimulation. Time-course analysis showed that this was an early event, beginning as soon as 5 min after exposure to ephrin B2/Fc and lasting for at least 60 min (Fig. 1A). Using phosphospecific antibodies, we furthermore demonstrated that EphB1 induces paxillin phosphorylation at Tyr-31 and Tyr-118 (Fig. 1B), two tyrosine residues which have been shown to play an important role in cell migration in various cancer cell lines (10, 13).

View larger version (31K): [in this window] [in a new window]   FIG. 1. Activated EphB1 induces phosphorylation of paxillin at Tyr-31 and Tyr-118. Serum-starved P19 (left panels) or CHO-EphB1 (right panels) were stimulated with 0.5–1 µg ml–1 ephrin B2/Fc for the indicated times (see "Experimental Procedures"). A, paxillin-immunoprecipitates were immunoblotted with anti-phosphotyrosine 4G10-HRP or anti-paxillin. B, 40 µg of lysates were immunoblotted with anti-pTyr-31 or anti-pTyr-118 paxillin as indicated; stripped blots were reprobed with anti-paxillin. Blots are representative of at least three independent experiments.

View larger version (33K): [in this window] [in a new window]   FIG. 2. EphB1 associates with paxillin and promotes tyrosine phosphorylation of FAK. Serum-starved P19 (left panels) or CHO-EphB1 (right panels) were stimulated with ephrin B2/Fc for the indicated times. A, FAK was immunoprecipitated with rabbit anti-FAK and immunoblotted with 4G10-HRP. B, paxillinimmunoprecipitates were immunoblotted with anti-EphB1, anti-FAK, or anti-paxillin as indicated. Blots are representative of at least three independent experiments.

View larger version (31K): [in this window] [in a new window]   FIG. 3. EphB1-induced paxillin phosphorylation at Tyr-31/Tyr-118 requires c-Src and is necessary for cell migration. A, CHO-EphB1 (left panels) or P19 (right panels) were stimulated with ephrin B2/Fc after pretreatment with PP2 (10 µM) or PP3 (data not shown) as described (see "Experimental Procedures"). Paxillin-immunoprecipitates were immunoblotted with anti-phosphotyrosine; stripped blots were reprobed with anti-paxillin. B, CHO-EphB1 transiently transfected with vector or dominant-negative, kinase-dead (K295R/Y527F) c-Src were stimulated as described with 1 µgml–1 ephrin B2/Fc. Paxillin-immunoprecipitates were immunoblotted with anti-phosphotyrosine; stripped blots were reprobed with anti-paxillin. To confirm similar transfection efficiency, 40 µg of lysates were immunoblotted with anti-c-Src. Blots are representative of at least three independent experiments. C, CHO-EphB1 was transiently transfected with vector, wild-type paxillin, or Tyr-31/Tyr-118 paxillin mutant. 48 h after transfection, cell migration was assessed as described (see "Experimental Procedures"). Results are representative of at least five independent experiments and represent the mean of triplicate wells ± S.E. *, p < 0.05.

Finally, to address the role of paxillin phosphorylation in EphB1-mediated cell migration, we overexpressed a Y31F/Y118F paxillin mutant in CHO-EphB1. We showed a 40% reduction in cell migratory behavior as compared with vector-transfected cells (Fig. 3C). To study this effect in a cellular system endogenously expressing EphB1, we transfected the same mutant into P19 cells: we saw a similar, although weaker effect on cell migration (30% reduction, data not shown). However, the transfection efficiency in P19 was only around 40%. Together these findings show that in CHO-EphB1 and P19 cells, paxillin tyrosine phosphorylation is required for proper cell migration.

EphB1-paxillin Interaction Is Mediated by Nck and Requires the LD4 Motif of Paxillin—Paxillin contains a number of motifs that mediate protein-protein interactions, including multiple SH2- and SH3-binding domains that mediate association with the Crk, Src, and Csk families, four LIM domains that target paxillin to focal adhesions, and five leucine-rich sequences with the consensus LDXLLXXL (termed LD motifs). These paxillin LD motifs mediate interactions with several structural and regulatory proteins that are important for coordinating changes in the actin cytoskeleton associated with cell motility and cell adhesion (reviewed in Refs. 14 and 15). Transfection of CHO-EphB1 with an LD4 deletion mutant (paxillin LD4) clearly reduced the association between activated EphB1 and paxillin, as well as the level of paxillin phosphorylation at Tyr-31 and Tyr-118 (Fig. 4A). Moreover, paxillin LD4 showed a reduced cell migration in response to ephrin B2 stimulation (Fig. 4B). Interestingly, overexpressing a paxillin LD2 deletion mutant (paxillin LD2) lacking an important FAK-binding site (9) did not inhibit EphB1-induced cell migration, nor did it disrupt the EphB1-paxillin association. This finding is in keeping with previous studies (9) and suggests that in the present cellular systems, FAK is not a key player in EphB1-directed cell migration, although it is phosphorylated by and associates with EphB1.

View larger version (45K): [in this window] [in a new window]   FIG. 4. EphB1-Nck-paxillin interaction requires the LD4 motif of paxillin and Tyr-594 of EphB1. A, CHO-EphB1 was transiently transfected with vector, wild-type paxillin, or mutant paxillin LD4 or paxillin LD2. 40 µg of lysates were immunoblotted with anti-pTyr31-paxillin or anti-pTyr118-paxillin. Paxillin-immunoprecipitates were immunoblotted with anti-HA; stripped blots were reprobed with anti-paxillin. B, CHO-EphB1 was transiently transfected with vector, wild-type paxillin, or mutant paxillin LD4 or paxillin LD2 (4 or 6 µg of DNA as indicated). 48 h after transfection, cell migration was assessed as described (see "Experimental Procedures"). Results are representative of at least five independent experiments and represent the mean of triplicate wells ± S.E. ***, p < 0.001. C, CHO-EphB1, P19, or HRMEC were stimulated as described. Nck-immunoprecipitates were immunoblotted with anti-HA, anti-paxillin, or anti-Nck as indicated. D, CHO cells were transiently transfected with vector, HA-tagged, wild-type EphB1, Y594F-EphB1, or Y929F-EphB1 mutants. Paxillin-immunoprecipitates were immunoblotted with anti-HA; stripped blots were reprobed with anti-paxillin. To confirm similar transfection efficiency, 40 µg of lysates were immunoblotted with anti-HA. Blots are representative of at least three independent experiments.

	DISCUSSION

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES

 
In this study, we provide evidence that tyrosine phosphorylation of two major phosphorylation sites of the adaptor protein paxillin plays a central role in EphB1-mediated cell migration. We show that activated EphB1 induces the phosphorylation of Tyr-31 and Tyr-118 residues of paxillin in a c-Src-dependent manner.

Paxillin becomes phosphorylated on tyrosine in response to various receptor tyrosine kinases, including platelet-derived growth factor, epidermal growth factor, and nerve growth factor (14). Recently, Carter et al. (6) identified EphA2, FAK, and p130^cas as the most heavily tyrosine-phosphorylated proteins in NIH-3T3 cells plated on ephrin A1-coated surface. The authors also showed that paxillin too was inducibly phosphorylated in response to ephrin A1 stimulation. However, because paxillin was not the major ephrin A-dependent phosphotyrosyl protein, they did not further characterize the phosphorylated tyrosine residues. Our findings suggest that, in contrast to EphA2 signaling, ligand-activated EphB1 preferentially targets paxillin at Tyr-31 and Tyr-118. Importantly, expression of a paxillin mutant lacking these two important phosphorylation sites resulted in a reduced migration in response to ephrin B2 stimulation. To date, the role of Tyr-31/Tyr-118 on cell motility has been quite controversial: Yano et al. (18) showed that in MM1 hepatoma cells, a paxillin mutant with substitutions of the four tyrosine phosphorylation sites of paxillin had no effect on cell invasive behavior. In contrast, Petit et al. (10) demonstrated that in NBT-II bladder carcinoma cells, expression of Tyr-31/Tyr-118 paxillin impaired cell motility on collagen by 50%. More recently, Tsubouchi et al. (13) showed that paxillin Tyr-31/Tyr-118 were essential for efficient membrane spreading and ruffling during adhesion and migration of NmuMG cells. Differences in the cellular context or the experimental design may account for these disparate results.

In an effort to dissect the molecular mechanisms underlying the interaction between EphB1 and paxillin, we performed another series of dominant-negative experiments. We demonstrated that kinase active c-Src is necessary for the tyrosine phosphorylation of paxillin in response to EphB1 stimulation. We confirmed these results by performing pharmacological inhibition experiments with the Src-specific inhibitor PP2. These findings highlight a new aspect of the role of c-Src in EphB1 signaling. Indeed, in a recent publication (8), we showed that EphB1 associates with the adaptor protein p52^Shc and activates the MAPK/ERK pathway in a c-Src-dependent manner. Furthermore, expression of dominant-negative, kinase-dead c-Src inhibited EphB1-dependent cell adhesion and migration. The data presented here suggest that in addition to MAPK activation, c-Src also regulates EphB1-dependent chemotaxis through tyrosine phosphorylation of paxillin.

Finally, we showed that, not only in CHO-EphB1, but also in P19 and primary human renal microvascular endothelial cells, ligand-activated EphB1 forms a complex with Nck and paxillin. This interaction was interrupted by the expression of either a paxillin LD4 deletion mutant or of Y594F-EphB1 lacking the Nck-binding site. Taken together, these experiments strongly suggest that EphB1 indirectly associates with paxillin through the intermediary of the adaptor protein Nck and the LD4 motif of paxillin.

In conclusion, we have made the novel observation that EphB1 induces tyrosine phosphorylation of paxillin at Tyr-31 and Tyr-118 in a c-Src-dependent manner. Furthermore, ligand-activated EphB1 builds a complex with Nck, paxillin, and FAK in an interaction requiring Tyr-594 of EphB1 and the LD4 motif of paxillin. The concerted actions of EphB1, Nck, and paxillin, in turn, appear to play a significant role in EphB1-mediated cell migration (Fig. 5).

View larger version (22K): [in this window] [in a new window]   FIG. 5. Proposed model of the EphB1-paxillin interaction. A proposed model of the molecular mechanisms of the EphB1-paxillin association is shown. Ligand-activated EphB1 recruits the adaptor protein Nck through the Tyr-594 residue. In turn, Nck forms a complex with paxillin, presumably through the LD4 motif of paxillin. On the other hand, c-Src is activated after binding to Tyr-600 of EphB1. Autophosphorylated c-Src (Tyr418-cSrc) then phosphorylates Tyr-31 and Tyr-118 of paxillin, promoting EphB1-dependent cell migration.

	FOOTNOTES

 
^* This work was supported by Swiss National Science Foundation Grants 31-59419.99 and 32-63182.00 (to U. H.-D.) and National Institutes of Health Grant GM47607 (to C. E. T.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

^|| To whom correspondence should be addressed: Div. of Nephrology, Dept. of Clinical Research, University of Bern, CH-3010 Bern, Switzerland. Tel.: 41-31-632-3141 or -3144; Fax: 41-31-632-9734; E-mail: uyen.huynh-do{at}insel.ch.

¹ The abbreviations used are: NIK, Nck-interacting Ste20 kinase; FAK, focal adhesion kinase; ERK, extracellular signal related kinase; HA, hemagglutinin; HRMEC, human renal microvascular endothelial cells; CHO, Chinese hamster ovary.

	ACKNOWLEDGMENTS

 
We thank Drs. Elke Stein (Yale University, New Haven, CT), Thomas Daniel (Ambrx Inc., San Diego, CA), Brigitte Frey and Felix Frey (University of Bern, Bern, Switzerland) for encouragement and critical comments on the manuscript.

	REFERENCES

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES

 

1. Mellitzer, G., Xu, Q., and Wilkinson, D. G. (2000) Curr. Opin. Neurobiol. 10, 400–408[CrossRef][Medline] [Order article via Infotrieve]
2. Contractor, A., Rogers, C., Maron, C., Henkemeyer, M., Swanson, G. T., and Heinemann, S. F. (2002) Science 296, 1864–1869[Abstract/Free Full Text]
3. Huynh-Do, U., Stein, E., Lane, A. A., Liu, H., Cerretti, D. P., and Daniel, T. O. (1999) EMBO J. 18, 2165–2173[CrossRef][Medline] [Order article via Infotrieve]
4. Becker, E., Huynh-Do, U., Holland, S., Pawson, T., Daniel, T. O., and Skolnik, E. Y. (2000) Mol. Cell. Biol. 20, 1537–1545[Abstract/Free Full Text]
5. Miao, H., Burnett, E., Kinch, M., Simon, E., and Wang, B. (2000) Nat. Cell Biol. 2, 62–69[CrossRef][Medline] [Order article via Infotrieve]
6. Carter, N., Nakamoto, T., Hirai, H., and Hunter, T. (2002) Nat. Cell Biol. 4, 565–573[Medline] [Order article via Infotrieve]
7. Davy, A., and Robbins, S. M. (2000) EMBO J. 19, 5396–5405[CrossRef][Medline] [Order article via Infotrieve]
8. Vindis, C., Cerretti, D. P., Daniel, T. O., and Huynh-Do, U. (2003) J. Cell Biol. 162, 661–671[Abstract/Free Full Text]
9. West, K. A., Zhang, H., Brown, M. C., Nikolopoulos, S. N., Riedy, M. C., Horwitz, A. F., and Turner, C. E. (2001) J. Cell Biol. 154, 161–176[Abstract/Free Full Text]
10. Petit, V., Boyer, B., Lentz, D., Turner, C. E., Thiery, J. P., and Valles, A. M. (2000) J. Cell Biol. 148, 957–970[Abstract/Free Full Text]
11. Stein, E., Huynh-Do, U., Lane, A. A., Cerretti, D. P., and Daniel, T. O. (1998) J. Biol. Chem. 273, 1303–1308[Abstract/Free Full Text]
12. Han, D. C., Shen, T. L., Miao, H., Wang, B., and Guan, J. L. (2002) J. Biol. Chem. 277, 45655–45661[Abstract/Free Full Text]
13. Tsubouchi, A., Sakakura, J., Yagi, R., Mazaki, Y., Schaefer, E., Yano, H., and Sabe, H. (2002) J. Cell Biol. 159, 673–683[Abstract/Free Full Text]
14. Schaller, M. D. (2001) Oncogene 20, 6459–6472[CrossRef][Medline] [Order article via Infotrieve]
15. Turner, C. E. (2000) Nat. Cell Biol. 2, E231-E236[CrossRef][Medline] [Order article via Infotrieve]
16. Nikolopoulos, S. N., and Turner, C. E. (2001) J. Biol. Chem. 276, 23499–23505[Abstract/Free Full Text]
17. Turner, C. E., Brown, M. C., Perrotta, J. A., Riedy, M. C., Nikolopoulos, S. N., McDonald, A. R., Bagrodia, S., Thomas, S., and Leventhal, P. S. (1999) J. Cell Biol. 145, 851–863[Abstract/Free Full Text]
18. Yano, H., Uchida, H., Iwasaki, T., Mukai, M., Akedo, H., Nakamura, K., Hashimoto, S., and Sabe, H. (2000) Proc. Natl. Acad. Sci. U. S. A. 97, 9076–9081[Abstract/Free Full Text]

CiteULike

Complore

Connotea

Del.icio.us

Digg

Reddit

Technorati

This article has been cited by other articles:

				C. Badowski, G. Pawlak, A. Grichine, A. Chabadel, C. Oddou, P. Jurdic, M. Pfaff, C. Albiges-Rizo, and M. R. Block Paxillin Phosphorylation Controls Invadopodia/Podosomes Spatiotemporal Organization Mol. Biol. Cell, February 1, 2008; 19(2): 633 - 645. [Abstract] [Full Text] [PDF]

				S. Guan, M. Chen, D. Woodley, and W. Li Nck{beta} Adapter Controls Neuritogenesis by Maintaining the Cellular Paxillin Level Mol. Cell. Biol., September 1, 2007; 27(17): 6001 - 6011. [Abstract] [Full Text] [PDF]

				O. Salvucci, M. de la Luz Sierra, J. A. Martina, P. J. McCormick, and G. Tosato EphB2 and EphB4 receptors forward signaling promotes SDF-1-induced endothelial cell chemotaxis and branching remodeling Blood, November 1, 2006; 108(9): 2914 - 2922. [Abstract] [Full Text] [PDF]

				N.-Y. Yang, E. B. Pasquale, L. B. Owen, and I. M. Ethell The EphB4 Receptor-tyrosine Kinase Promotes the Migration of Melanoma Cells through Rho-mediated Actin Cytoskeleton Reorganization J. Biol. Chem., October 27, 2006; 281(43): 32574 - 32586. [Abstract] [Full Text] [PDF]

				M. M. Vihanto, C. Vindis, V. Djonov, D. P. Cerretti, and U. Huynh-Do Caveolin-1 is required for signaling and membrane targeting of EphB1 receptor tyrosine kinase J. Cell Sci., June 1, 2006; 119(11): 2299 - 2309. [Abstract] [Full Text] [PDF]

				C. Quiniou, F. Sennlaub, M. H. Beauchamp, D. Checchin, I. Lahaie, S. Brault, F. Gobeil Jr., M. Sirinyan, A. Kooli, P. Hardy, et al. Dominant Role for Calpain in Thromboxane-Induced Neuromicrovascular Endothelial Cytotoxicity J. Pharmacol. Exp. Ther., February 1, 2006; 316(2): 618 - 627. [Abstract] [Full Text] [PDF]

				M. L. Moeller, Y. Shi, L. F. Reichardt, and I. M. Ethell EphB Receptors Regulate Dendritic Spine Morphogenesis through the Recruitment/Phosphorylation of Focal Adhesion Kinase and RhoA Activation J. Biol. Chem., January 20, 2006; 281(3): 1587 - 1598. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) All Versions of this Article: 279/27/27965    most recent M401295200v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Vindis, C. Articles by Huynh-Do, U. Search for Related Content PubMed PubMed Citation Articles by Vindis, C. Articles by Huynh-Do, U. Social Bookmarking                      What's this?